NCT02310321 2025-09-02
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
Phase 1/2 Completed
Clinical Trials
15 trialsNCT01518556 2025-03-20
IDAML
Konkuk University Medical Center
Phase 1/2 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02464657 2021-10-07
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00831766 2020-12-22
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02046122 2020-12-03
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Duke University
Phase 1/2 Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02306291 2019-05-17
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
GlycoMimetics Incorporated
Phase 1/2 Completed
NCT00542971 2018-08-23
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01435343 2017-04-25
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
PETHEMA Foundation
Phase 1/2 Completed
NCT00469859 2017-03-15
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Children's Oncology Group
Phase 1/2 Completed
NCT00878722 2015-07-28
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Valerio Therapeutics
Phase 1/2 Completed
NCT00096122 2014-05-26
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed